Education is not enough. People also need access to actual services.
In the Philippines, where one of the Asia-Pacific region's fastest-growing HIV epidemics unfolds, five hundred people living with HIV have quietly completed a full course of HPV vaccination — a small but meaningful act of preventive justice. A collaboration between MSD, PHAP Cares Foundation, and Project Red Ribbon delivered 1,500 doses over the course of a year, reaching immunocompromised individuals whose elevated cancer risk from HPV has long gone unaddressed within standard HIV care. The initiative asks a deeper question that health systems everywhere must eventually answer: when we treat a condition, do we see the whole person, or only the diagnosis?
- People living with HIV face sharply higher risks of persistent HPV infections that can progress to cancer, yet this vulnerability is rarely acknowledged — or acted upon — within existing HIV care programs.
- The Philippines is navigating one of the steepest HIV growth curves in the Asia-Pacific, creating pressure on health advocates to move beyond treatment and close dangerous gaps in prevention.
- A three-way partnership between a pharmaceutical company, a health foundation, and a patient advocacy group completed distribution of 1,500 HPV vaccine doses to 500 PLHIV beneficiaries, with all finishing their three-dose regimen by June 2026.
- A persistent misconception — that HPV vaccination is primarily a concern for women — has left many vulnerable populations, including PLHIV of all genders, without access to a protection they urgently need.
- With the first phase complete, stakeholders are now pushing for HPV vaccination to be formally integrated into national HIV treatment programs, reframing HIV care as something holistic rather than narrowly pharmaceutical.
Five hundred people living with HIV in the Philippines have completed a full three-dose HPV vaccination course, closing out a year-long initiative that brought preventive care to a population carrying disproportionate health risk. The collaboration — between pharmaceutical company MSD, the PHAP Cares Foundation, and advocacy group Project Red Ribbon — distributed 1,500 doses to immunocompromised individuals who would otherwise have had little access to this protection. All beneficiaries received their final dose by June 2026.
The effort arrives at a critical moment. The Philippines is experiencing one of the fastest-growing HIV epidemics in the Asia-Pacific region, and people living with HIV face significantly elevated risk of persistent HPV infections that can develop into various cancers. Yet HPV vaccination remains largely absent from standard HIV care protocols, and awareness of this heightened vulnerability is low among both patients and some providers.
Dr. Maria Rosarita Siasoco of PHAP Cares Foundation described the initiative as both a public health necessity and a matter of equity — a recognition that preventive care is not consistently woven into the pathways available to people living with HIV. Project Red Ribbon's president, Ico Johnson, framed the completion as proof that when access is genuinely provided, people will commit to their own health. The organization has since expanded its services to include HPV-related consultations alongside its existing HIV care work.
MSD's Karlo Paredes pointed to a stubborn misconception — that HPV vaccination is primarily for women — as one of the barriers this initiative helped dismantle. The successful administration of all doses within a single year, he suggested, illustrates what becomes possible when the pathway to care is made clear. Stakeholders are now calling for HPV vaccination to be integrated into national HIV treatment programs, signaling a broader shift toward holistic, preventive care for one of the country's most vulnerable populations.
Five hundred people living with HIV in the Philippines have completed a full course of HPV vaccination, marking the end of a year-long effort to deliver preventive care to a population facing disproportionate health risks. The initiative, a collaboration between pharmaceutical company MSD, the PHAP Cares Foundation, and the advocacy group Project Red Ribbon, distributed 1,500 vaccine doses—three per person—to immunocompromised individuals who would otherwise have had limited access to this protection. All beneficiaries finished their final dose by June 2026.
The timing reflects an urgent public health moment. The Philippines is experiencing one of the fastest-growing HIV epidemics in the Asia-Pacific region, and healthcare advocates argue that prevention must accompany treatment. People living with HIV face a significantly elevated risk of persistent HPV infections, which can develop into various cancers. Yet HPV vaccination remains largely absent from standard HIV care protocols, and many patients and even some providers remain unaware of this heightened vulnerability.
Dr. Maria Rosarita Siasoco, Executive Director of PHAP Cares Foundation, framed the initiative as both a public health necessity and a matter of equity. She noted that preventive interventions like HPV vaccination and early screening are not always woven into the care pathways available to people living with HIV. The foundation's approach was to look beyond statistics—to recognize that each case represents a person and a family in need of support. She emphasized that the Philippines' surging HIV numbers demand urgent action, and that closing gaps in awareness and access to prevention is part of that response. Many people living with HIV, she explained, simply do not know they face heightened HPV risk, and many HIV programs do not routinely offer or discuss HPV vaccines.
Project Red Ribbon, which managed the distribution, delivered the vaccines to 500 clients across its network. The organization's president, Ico Johnson, described the completion as evidence that when access is provided, people will commit to their health. He positioned the initiative within a broader vision of client-centered care—one that extends beyond HIV treatment alone to address sexually transmitted infections and related health risks. Project Red Ribbon has since expanded its services to include HPV-related consultations and treatment alongside its existing HIV care and advocacy work.
Karlo Paredes, MSD's Market Access and Corporate Affairs Director, highlighted a persistent misconception: that HPV vaccination is primarily for women. In reality, he noted, many vulnerable populations stand to benefit, particularly people living with HIV. The fact that all 1,500 doses were administered within a year, he suggested, demonstrates what becomes possible when barriers to access are removed. People will show up for their health when the pathway is clear.
The initiative represents a shift in how HIV care is conceptualized in the Philippines. Rather than treating HIV as an isolated condition requiring medication alone, the collaborating organizations are arguing for a more holistic approach—one that integrates prevention of related infections and cancers into the standard care model. As this first phase concludes, stakeholders are calling for the integration of HPV vaccination into HIV treatment programs nationwide, signaling a move toward comprehensive, preventive healthcare for one of the country's most vulnerable populations.
Notable Quotes
PLHIVs face a significantly higher risk of persistent HPV infections, which can lead to different forms of cancer. Despite this elevated risk, preventive interventions like HPV vaccination and early screening are not always fully integrated into HIV care pathways.— Dr. Maria Rosarita Siasoco, Executive Director of PHAP Cares Foundation
Finishing all 1,500 doses within one year proves that when access is provided, people will come forward and commit to protecting their health.— Karlo Paredes, MSD Market Access and Corporate Affairs Director
The Hearth Conversation Another angle on the story
Why does someone living with HIV need an HPV vaccine in the first place? Aren't they already dealing with enough?
That's exactly the thinking that has left this gap unfilled for so long. When your immune system is compromised by HIV, your body can't clear HPV infections the way it normally would. That means the virus persists, and persistent HPV infection is what leads to cancers—cervical, anal, throat cancers. So yes, they're dealing with HIV treatment, but without HPV protection, they're facing an additional, preventable cancer risk.
So this is about preventing cancer, not preventing HPV transmission itself?
Both, actually. But the cancer prevention is the more urgent piece for people already living with HIV. The vaccine works best before exposure, but even for someone who's already encountered HPV, vaccination can still offer protection against strains they haven't met yet. For immunocompromised people, that matters.
Why did it take until 2025 for this to happen? HPV vaccines have existed for years.
Because HPV vaccination was never really built into HIV care in the Philippines. The systems don't talk to each other. An HIV clinic focuses on viral load and CD4 counts. An HPV vaccine sits in a different part of the healthcare world. And there's a knowledge gap too—many providers don't think about it, many patients don't know they're at risk. This project had to create the bridge.
What changes now that 500 people have been vaccinated?
The real test is whether this becomes routine. If HPV vaccination stays a one-off project, it hasn't solved the problem. But the organizations involved are pushing for it to be integrated into standard HIV care nationwide. That would mean every person newly diagnosed with HIV gets offered HPV vaccination as part of their treatment plan, the way they get offered antiretroviral drugs.
And if that doesn't happen?
Then you've helped 500 people, which matters enormously to those 500 people and their families. But you haven't changed the system. The gaps in awareness and access remain for everyone else.